ArticleCureus2025
Oral Cornstarch and Glycyrrhizin Improve Severe Liver Injury Caused by Glycogen Storage Disease Type IXa.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A previously healthy 18-month-old boy presented with hepatomegaly, accompanied by liver injury. Imaging and liver biopsy findings suggested a hepatic glycogen storage disease (GSD) but not GSD type I. Genetic testing revealed a partial deletion of the PHKA2 gene, confirming the diagnosis of GSD type IXa. Initial treatment included ursodeoxycholic acid and portioned meals. However, the boy's liver injury continued to worsen. Subsequently, nightly oral cornstarch after meals and oral glycyrrhizin were introduced. Following the addition of cornstarch and glycyrrhizin, the patient's liver injury significantly improved. Liver injury caused by GSD is likely due to excessive glycogen accumulation in the hepatocytes. However, the detailed mechanism is unclear, particularly the minimal inflammatory cell infiltration observed in this case. While GSD IX has a good prognosis and resolves spontaneously, some patients develop hepatic fibrosis and adenomas. Cornstarch supplementation is a mainstay treatment for GSD to prevent hypoglycemia. It may also contribute to improved liver function by moderating glycogen buildup. The glycyrrhizin has also shown potential in reducing mitochondrial damage via another mechanism in this case, but additional research is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.